Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Impact · against what's priced in

Pharming's Q3 results show strong operating leverage and positive clinical progress for leniolisib, providing a near-term catalyst with upcoming CVID data. While the revenue guidance upper bound was slightly lowered, the significant expansion in operating profit and successful Joenja growth drive a positive outlook.

PHARM+0.60

No priced-in read yet